Liver-Regenerative Transplantation

Regrow and Reset

A. Collin de l'Hortet, kazuki takeishi, J. Guzman-Lepe, K. Handa, K. Matsubara, K. Fukumitsu, K. Dorko, S. C. Presnell, H. Yagi, A. Soto-Gutierrez

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Liver transplantation, either a partial liver from a living or deceased donor or a whole liver from a deceased donor, is the only curative therapy for severe end-stage liver disease. Only one-third of those on the liver transplant waiting list will be transplanted, and the demand for livers is projected to increase 23% in the next 20 years. Consequently, organ availability is an absolute constraint on the number of liver transplants that can be performed. Regenerative therapies aim to enhance liver tissue repair and regeneration by any means available (cell repopulation, tissue engineering, biomaterials, proteins, small molecules, and genes). Recent experimental work suggests that liver repopulation and engineered liver tissue are best suited to the task if an unlimited availability of functional induced pluripotent stem (iPS)–derived liver cells can be achieved. The derivation of iPS cells by reprogramming cell fate has opened up new lines of investigation, for instance, the generation of iPS-derived xenogeneic organs or the possibility of simply inducing the liver to reprogram its own hepatocyte function after injury. We reviewed current knowledge about liver repopulation, generation of engineered livers and reprogramming of liver function. We also discussed the numerous barriers that have to be overcome for clinical implementation.

Original languageEnglish
Pages (from-to)1688-1696
Number of pages9
JournalAmerican Journal of Transplantation
Volume16
Issue number6
DOIs
Publication statusPublished - Jan 1 2016
Externally publishedYes

Fingerprint

Liver Transplantation
Liver
Transplants
Induced Pluripotent Stem Cells
End Stage Liver Disease
Waiting Lists
Biocompatible Materials
Tissue Engineering
Regeneration
Hepatocytes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Collin de l'Hortet, A., takeishi, K., Guzman-Lepe, J., Handa, K., Matsubara, K., Fukumitsu, K., ... Soto-Gutierrez, A. (2016). Liver-Regenerative Transplantation: Regrow and Reset. American Journal of Transplantation, 16(6), 1688-1696. https://doi.org/10.1111/ajt.13678

Liver-Regenerative Transplantation : Regrow and Reset. / Collin de l'Hortet, A.; takeishi, kazuki; Guzman-Lepe, J.; Handa, K.; Matsubara, K.; Fukumitsu, K.; Dorko, K.; Presnell, S. C.; Yagi, H.; Soto-Gutierrez, A.

In: American Journal of Transplantation, Vol. 16, No. 6, 01.01.2016, p. 1688-1696.

Research output: Contribution to journalReview article

Collin de l'Hortet, A, takeishi, K, Guzman-Lepe, J, Handa, K, Matsubara, K, Fukumitsu, K, Dorko, K, Presnell, SC, Yagi, H & Soto-Gutierrez, A 2016, 'Liver-Regenerative Transplantation: Regrow and Reset', American Journal of Transplantation, vol. 16, no. 6, pp. 1688-1696. https://doi.org/10.1111/ajt.13678
Collin de l'Hortet A, takeishi K, Guzman-Lepe J, Handa K, Matsubara K, Fukumitsu K et al. Liver-Regenerative Transplantation: Regrow and Reset. American Journal of Transplantation. 2016 Jan 1;16(6):1688-1696. https://doi.org/10.1111/ajt.13678
Collin de l'Hortet, A. ; takeishi, kazuki ; Guzman-Lepe, J. ; Handa, K. ; Matsubara, K. ; Fukumitsu, K. ; Dorko, K. ; Presnell, S. C. ; Yagi, H. ; Soto-Gutierrez, A. / Liver-Regenerative Transplantation : Regrow and Reset. In: American Journal of Transplantation. 2016 ; Vol. 16, No. 6. pp. 1688-1696.
@article{19b9993445a8447eb0e32f6fc8dda300,
title = "Liver-Regenerative Transplantation: Regrow and Reset",
abstract = "Liver transplantation, either a partial liver from a living or deceased donor or a whole liver from a deceased donor, is the only curative therapy for severe end-stage liver disease. Only one-third of those on the liver transplant waiting list will be transplanted, and the demand for livers is projected to increase 23{\%} in the next 20 years. Consequently, organ availability is an absolute constraint on the number of liver transplants that can be performed. Regenerative therapies aim to enhance liver tissue repair and regeneration by any means available (cell repopulation, tissue engineering, biomaterials, proteins, small molecules, and genes). Recent experimental work suggests that liver repopulation and engineered liver tissue are best suited to the task if an unlimited availability of functional induced pluripotent stem (iPS)–derived liver cells can be achieved. The derivation of iPS cells by reprogramming cell fate has opened up new lines of investigation, for instance, the generation of iPS-derived xenogeneic organs or the possibility of simply inducing the liver to reprogram its own hepatocyte function after injury. We reviewed current knowledge about liver repopulation, generation of engineered livers and reprogramming of liver function. We also discussed the numerous barriers that have to be overcome for clinical implementation.",
author = "{Collin de l'Hortet}, A. and kazuki takeishi and J. Guzman-Lepe and K. Handa and K. Matsubara and K. Fukumitsu and K. Dorko and Presnell, {S. C.} and H. Yagi and A. Soto-Gutierrez",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/ajt.13678",
language = "English",
volume = "16",
pages = "1688--1696",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Liver-Regenerative Transplantation

T2 - Regrow and Reset

AU - Collin de l'Hortet, A.

AU - takeishi, kazuki

AU - Guzman-Lepe, J.

AU - Handa, K.

AU - Matsubara, K.

AU - Fukumitsu, K.

AU - Dorko, K.

AU - Presnell, S. C.

AU - Yagi, H.

AU - Soto-Gutierrez, A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Liver transplantation, either a partial liver from a living or deceased donor or a whole liver from a deceased donor, is the only curative therapy for severe end-stage liver disease. Only one-third of those on the liver transplant waiting list will be transplanted, and the demand for livers is projected to increase 23% in the next 20 years. Consequently, organ availability is an absolute constraint on the number of liver transplants that can be performed. Regenerative therapies aim to enhance liver tissue repair and regeneration by any means available (cell repopulation, tissue engineering, biomaterials, proteins, small molecules, and genes). Recent experimental work suggests that liver repopulation and engineered liver tissue are best suited to the task if an unlimited availability of functional induced pluripotent stem (iPS)–derived liver cells can be achieved. The derivation of iPS cells by reprogramming cell fate has opened up new lines of investigation, for instance, the generation of iPS-derived xenogeneic organs or the possibility of simply inducing the liver to reprogram its own hepatocyte function after injury. We reviewed current knowledge about liver repopulation, generation of engineered livers and reprogramming of liver function. We also discussed the numerous barriers that have to be overcome for clinical implementation.

AB - Liver transplantation, either a partial liver from a living or deceased donor or a whole liver from a deceased donor, is the only curative therapy for severe end-stage liver disease. Only one-third of those on the liver transplant waiting list will be transplanted, and the demand for livers is projected to increase 23% in the next 20 years. Consequently, organ availability is an absolute constraint on the number of liver transplants that can be performed. Regenerative therapies aim to enhance liver tissue repair and regeneration by any means available (cell repopulation, tissue engineering, biomaterials, proteins, small molecules, and genes). Recent experimental work suggests that liver repopulation and engineered liver tissue are best suited to the task if an unlimited availability of functional induced pluripotent stem (iPS)–derived liver cells can be achieved. The derivation of iPS cells by reprogramming cell fate has opened up new lines of investigation, for instance, the generation of iPS-derived xenogeneic organs or the possibility of simply inducing the liver to reprogram its own hepatocyte function after injury. We reviewed current knowledge about liver repopulation, generation of engineered livers and reprogramming of liver function. We also discussed the numerous barriers that have to be overcome for clinical implementation.

UR - http://www.scopus.com/inward/record.url?scp=84978805141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978805141&partnerID=8YFLogxK

U2 - 10.1111/ajt.13678

DO - 10.1111/ajt.13678

M3 - Review article

VL - 16

SP - 1688

EP - 1696

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 6

ER -